MetaCap

Atara Biotherapeutics (ATRA) vs Coherus Oncology (CHRS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Atara Biotherapeutics (ATRA) has outperformed Coherus Oncology (CHRS) over the past year, losing 53.7% versus a loss of 68.1%. Over five years, CHRS leads with a -98.0% price change compared with -98.6% for ATRA. Atara Biotherapeutics is the larger company by market cap ($64.5 million vs $57.1 million), about 1.1 times the size, while Coherus Oncology is growing revenue faster (+59.8% vs -6.3%).

Coherus Oncology converts more of its revenue into profit, with a net margin of 398.4% versus 27.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATRA-53.73%CHRS-68.12%
+126%+23%-79%
Nov 21, 20251 yearNov 20, 2026
ATRA-98.62%CHRS-98.00%
+5%-50%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATRA versus CHRS key metrics
MetricATRACHRS
Share price$6.33$0.3698
Market cap$64.49M$57.15M
1-day change-0.16%-4.47%
YTD return-65.01%-73.96%
1-year return-53.73%-68.12%
5-year return-98.56%-97.99%
Forward P/E3.96—
EPS (TTM)$-1.12$-1.12
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$120.77M$42.17M
Revenue growth (YoY)-6.33%+59.81%
Net income (latest FY)$32.69M$168.02M
Gross margin—67.24%
Operating margin29.69%-429.51%
Net margin27.07%398.43%
52-week high$19.15$2.62
52-week low$3.92$0.3628
Distance from 52-week high-66.94%-85.86%
Analyst consensusbuystrong_buy
Avg. price target upside+115.96%+1995.73%
Average volume35.46K1.80M
Shares outstanding10.19M154.54M
Employees10144
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ATRA has outperformed CHRS by 14.4 percentage points over the past year.
  • Coherus Oncology is more profitable, keeping 398.4 cents of every revenue dollar as net income versus 27.1 cents for Atara Biotherapeutics.
  • Coherus Oncology grew revenue faster in its latest fiscal year (+59.81% vs -6.33%).

About Atara Biotherapeutics

ATRA stock →

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees

About Coherus Oncology

CHRS stock →

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees

ATRA vs CHRS FAQ

Which is bigger, Atara Biotherapeutics or Coherus Oncology?

Atara Biotherapeutics (ATRA) is larger, with a market capitalization of $64.49M compared with $57.15M for Coherus Oncology (CHRS).

Which stock has performed better over the past year, ATRA or CHRS?

ATRA returned -53.73% over the past 12 months, compared with -68.12% for CHRS (price return, excluding dividends). Past performance does not predict future results.

Are Atara Biotherapeutics and Coherus Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons